More sarcoma patients are beating the odds with pembrolizumab! This immunotherapy can change the treatment for limb sarcomas ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results ...
Medpage Today on MSN1d
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free SurvivalAdding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...
PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...
Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...
MedPage Today on MSN1d
Year in Review: Early Breast CancerNews in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...
Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival ...
Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...
Editor's note: This story has been revised to include additional comments. CHICAGO — In patients with stage IVB anaplastic ...
In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback